In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers
暂无分享,去创建一个
Qi Wang | Chuipu Cai | Pengfei Guo | Jiansong Fang | Feixiong Cheng | Huixiao Hong | Javid Moslehi | F. Cheng | H. Hong | Jiansong Fang | C. Cai | Qi Wang | J. Moslehi | Pengfei Guo
[1] F. Cheng,et al. Autoimmune Cardiotoxicity of Cancer Immunotherapy. , 2017, Trends in immunology.
[2] O. Sartor,et al. Cabazitaxel for castration-resistant prostate cancer – Authors' reply , 2011, The Lancet.
[3] Yangyang He,et al. Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery , 2014, Molecular Diversity.
[4] Jie Shen,et al. Adverse Drug Events: Database Construction and in Silico Prediction , 2013, J. Chem. Inf. Model..
[5] R. Altman,et al. Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.
[6] K. Red-Horse,et al. Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes as an In Vitro Model for Coxsackievirus B3–Induced Myocarditis and Antiviral Drug Screening Platform , 2014, Circulation research.
[7] M. Florescu,et al. Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer , 2017, American journal of therapeutics.
[8] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[9] Thomas C. Wiegers,et al. The Comparative Toxicogenomics Database: update 2017 , 2016, Nucleic Acids Res..
[10] Chuang Liu,et al. Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..
[11] F. Cheng,et al. Quantitative and systems pharmacology 4. Network-based analysis of drug pleiotropy on coronary artery disease. , 2019, European journal of medicinal chemistry.
[12] Luhua Lai,et al. Deep Learning for Drug-Induced Liver Injury , 2015, J. Chem. Inf. Model..
[13] Jai-Sing Yang,et al. Endoplasmic reticulum stress contributes to arsenic trioxide‐induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells , 2016, Environmental toxicology.
[14] B. Hasinoff,et al. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. , 2010, Toxicology and applied pharmacology.
[15] M. Baccarani,et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia , 2016, Leukemia.
[16] S. George,et al. Heart Failure: A Paraneoplastic Manifestation of Renal Cell Carcinoma – Reversed With Pazopanib , 2017, Clinical genitourinary cancer.
[17] V. Soomers,et al. Fatal heart failure in a young adult female sarcoma patient treated with pazopanib , 2017, Acta oncologica.
[18] Shujuan Jiang,et al. Acute myocardial infarction following erlotinib treatment for NSCLC: A case report. , 2016, Oncology letters.
[19] Tal Lorberbaum,et al. Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation. , 2016, Journal of the American College of Cardiology.
[20] Hsuan-Tien Lin,et al. A note on Platt’s probabilistic outputs for support vector machines , 2007, Machine Learning.
[21] John Platt,et al. Probabilistic Outputs for Support vector Machines and Comparisons to Regularized Likelihood Methods , 1999 .
[22] J. Yates,et al. Modeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety Assessment , 2015, CPT: pharmacometrics & systems pharmacology.
[23] Lei Yang,et al. Classification of Cytochrome P450 Inhibitors and Noninhibitors Using Combined Classifiers , 2011, J. Chem. Inf. Model..
[24] S. Lipshultz,et al. Chemotherapy-induced cardiotoxicity in children , 2017, Expert opinion on drug metabolism & toxicology.
[25] Heidi Ledford. Cancer experts unveil wishlist for US government ‘moonshot’ , 2016, Nature.
[26] M. Kalender,et al. Could erlotinib treatment lead to acute cardiovascular events in patients with lung adenocarcinoma after chemotherapy failure? , 2015, OncoTargets and therapy.
[27] Alasdair J. G. Gray,et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY , 2017, Nucleic Acids Res..
[28] J. Hureaux,et al. Maintenance Treatment by Erlotinib and Toxic Cardiomyopathy: A Case Report , 2016, Oncology.
[29] Comparative study of microtubule inhibitors--estramustine and natural podophyllotoxin conjugated PAMAM dendrimer on glioma cell proliferation. , 2013, European journal of medicinal chemistry.
[30] Kaitlyn M. Gayvert,et al. A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials. , 2016, Cell chemical biology.
[31] Nicholas P. Tatonetti,et al. An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval , 2016, Drug Safety.
[32] E. Matthews,et al. Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence. , 2010, Regulatory toxicology and pharmacology : RTP.
[33] J. Seidman,et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.
[34] S. Sleijfer,et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors , 2015, British Journal of Cancer.
[35] S. Polak,et al. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties , 2009, Journal of applied toxicology : JAT.
[36] Frederick P. Roth,et al. Chemical substructures that enrich for biological activity , 2008, Bioinform..
[37] J. Moslehi,et al. Cardiovascular Toxic Effects of Targeted Cancer Therapies. , 2016, The New England journal of medicine.
[38] Chuipu Cai,et al. Quantitative and Systems Pharmacology. 1. In Silico Prediction of Drug-Target Interactions of Natural Products Enables New Targeted Cancer Therapy , 2017, J. Chem. Inf. Model..
[39] Sebastian Schneeweiss,et al. Use of Health Care Databases to Support Supplemental Indications of Approved Medications , 2018, JAMA internal medicine.
[40] Tom Fawcett,et al. An introduction to ROC analysis , 2006, Pattern Recognit. Lett..
[41] Pierre Baldi,et al. Deep Architectures and Deep Learning in Chemoinformatics: The Prediction of Aqueous Solubility for Drug-Like Molecules , 2013, J. Chem. Inf. Model..
[42] Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. , 2015, Blood.
[43] Donald K. Wedding,et al. Discovering Knowledge in Data, an Introduction to Data Mining , 2005, Inf. Process. Manag..
[44] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[45] S. Vallurupalli,et al. Pazopanib- and bevacizumab-induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report , 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[46] Olivier Bodenreider,et al. The Unified Medical Language System (UMLS): integrating biomedical terminology , 2004, Nucleic Acids Res..
[47] CHUN WEI YAP,et al. PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..
[48] Nima Milani-Nejad,et al. Small and large animal models in cardiac contraction research: advantages and disadvantages. , 2014, Pharmacology & therapeutics.
[49] E. Seront,et al. Rapid and fatal acute heart failure induced by pazopanib , 2015, BMJ Case Reports.
[50] Mark R. Davies,et al. A new classifier-based strategy for in-silico ion-channel cardiac drug safety assessment , 2015, Front. Pharmacol..
[51] Praveen Shukla,et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells , 2017, Science Translational Medicine.
[52] D. Tavian,et al. Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity. , 2017, Current medicinal chemistry.
[53] Feixiong Cheng,et al. In silico ADMET prediction: recent advances, current challenges and future trends. , 2013, Current topics in medicinal chemistry.
[54] J. Irani. [Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma]. , 2007, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
[55] James W Kramer,et al. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. , 2013, Toxicology and applied pharmacology.
[56] Thomas Streichert,et al. Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue , 2016, PloS one.
[57] K. Hornbuckle,et al. Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999 , 2001 .
[58] Kashif Ali,et al. Follow-up of erlotinib related uveitis , 2012, BMJ Case Reports.
[59] E. Matthews,et al. Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities. , 2010, Regulatory toxicology and pharmacology : RTP.
[60] Santiago Vilar,et al. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. , 2008, Current topics in medicinal chemistry.
[61] Steven J. M. Jones,et al. Circos: an information aesthetic for comparative genomics. , 2009, Genome research.
[62] Jie Li,et al. Prediction of Polypharmacological Profiles of Drugs by the Integration of Chemical, Side Effect, and Therapeutic Space , 2013, J. Chem. Inf. Model..
[63] Rob Malouf,et al. A Comparison of Algorithms for Maximum Entropy Parameter Estimation , 2002, CoNLL.
[64] Hua Xu,et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs , 2012, J. Am. Medical Informatics Assoc..
[65] Patrick van der Smagt,et al. Introduction to neural networks , 1995, The Lancet.
[66] J. Dearden,et al. QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.
[67] Chris Morley,et al. Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.
[68] Gisbert Schneider,et al. Support vector machine applications in bioinformatics. , 2003, Applied bioinformatics.
[69] Qi Wang,et al. Discovery of neuroprotective compounds by machine learning approaches , 2016 .
[70] D. Cox. The Regression Analysis of Binary Sequences , 2017 .
[71] Chih-Jen Lin,et al. LIBSVM: A library for support vector machines , 2011, TIST.
[72] Zhongming Zhao,et al. Machine learning-based prediction of drug-drug interactions by integrating drug phenotypic, therapeutic, chemical, and genomic properties. , 2014, Journal of the American Medical Informatics Association : JAMIA.
[73] H. Maddock,et al. Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury. , 2014, Clinical science.
[74] K. Aonuma,et al. Cardiovascular toxic effects of targeted cancer therapy. , 2017, Japanese journal of clinical oncology.
[75] David S. Wishart,et al. DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..
[76] H. Korashy,et al. Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress. , 2016, Toxicology letters.